证券代码：601607 证券简称：上海医药 编号：临2025-099 重要内容提示： 上海医药集团股份有限公司 2025 年半年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、利润分配方案内容 经董事会决议，公司拟以实施权益分派股权登记日登记的总股本为基数实施 2025 年半年度利润分配。本次利润分配方案如下： 本 公 司 2025 年 半 年 度 实 现 合 并 归 属 于 上 市 公 司 股 东 的 净 利 润 4,458,864,876.61 元（未经审计），拟以截至 2025 年 6 月 30 日总股本 3,708,361,809 股为基数，向全体股东每 10 股派发现金红利 1.20 元（含税），合计拟派发现金 红利总额为 445,003,417.08 元（含税），占 2025 年半年度合并归属于上市公司 股东的净利润的 9.98%。2025 年半年度不进行资本公积金转增股本。 如在本公告披露之日起至实施权益分派股权登记日期间，公司总股本发生变 动的，公司拟以实施权益分派股权登记日的总股 ...

Financial Performance - For the first nine months of 2025, Shanghai Pharmaceuticals achieved a revenue of RMB 215.07 billion, representing a year-on-year growth of 2.60%[11] - The net profit attributable to shareholders for the same period was RMB 5.147 billion, a year-on-year increase of 26.96%, primarily due to a one-time special gain from changing accounting treatment for a joint venture[11] - The company's total profit for the period was CNY 1.48 billion, a decrease of 18.94% compared to the previous year[22] - The net profit attributable to shareholders was CNY 688.20 million, down 38.13% year-on-year[22] - The company's total profit for the first three quarters was ¥8.30 billion, up from ¥6.64 billion, reflecting an increase of approximately 25%[38] - Net profit for the first three quarters of 2025 was ¥5.99 billion, compared to ¥5.02 billion in 2024, marking an increase of approximately 19.2%[39] - The basic earnings per share rose to ¥1.39 from ¥1.09, indicating a growth of about 27.5%[39] Research and Development - Research and development expenses for the first nine months amounted to RMB 1.729 billion, accounting for 9.52% of the pharmaceutical manufacturing revenue[12] - The company has 57 new drug candidates in clinical trials, including 45 innovative drugs, with significant progress in various projects[12] - The BCD-085 project, an innovative monoclonal antibody, has submitted a new drug application for ankylosing spondylitis during the reporting period[12] - The company completed patient enrollment for the Phase III clinical trial of the traditional Chinese medicine product, Shenqi Sharuang Wan, aimed at treating cervical spondylotic myelopathy[13] - Research and development expenses were reported at ¥1.52 billion, slightly down from ¥1.62 billion, indicating a decrease of about 6.5%[38] - Research and development expenses decreased to CNY 270,894,446.73 in 2025 from CNY 419,246,826.18 in 2024, reflecting a reduction of approximately 35.3%[49] Business Segments - The company's pharmaceutical business achieved a revenue of CNY 73.48 billion in the current reporting period, representing a year-on-year increase of 4.65%[22] - The innovative drug business generated sales of CNY 40.7 billion, with a year-on-year growth of over 25%[19] - The import agency business reported sales of CNY 27.6 billion, reflecting a year-on-year increase of over 14%[19] - The company has 51 products in the rare disease treatment field, covering 67 rare disease conditions[18] - The company is actively participating in building a rare disease prevention and treatment ecosystem, enhancing drug accessibility[18] Assets and Liabilities - The total assets at the end of the reporting period were CNY 236.75 billion, an increase of 7.02% from the previous year[22] - The company's current assets totaled RMB 183.93 billion, up from RMB 171.82 billion in the previous year, indicating a year-over-year increase of about 7.1%[33] - The total liabilities reached RMB 147.12 billion, compared to RMB 137.47 billion in the previous year, reflecting an increase of approximately 7.3%[35] - The company's cash and cash equivalents stood at RMB 36.73 billion, slightly up from RMB 35.74 billion, showing a growth of about 2.8%[33] - The total equity of the company reached RMB 89.62 billion, an increase from RMB 83.74 billion, representing a growth of about 7.5%[35] - The total liabilities increased to approximately $27.4 billion in 2025 from $25.8 billion in 2024, suggesting a rise in financial obligations[46] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 92,942[28] - The top ten shareholders collectively hold 1,427,235,837 shares, accounting for 38.487% of the total share capital[30] - HKSCC NOMINEES LIMITED is the largest shareholder with 918,240,949 shares, representing 24.761% of the total[28] - Shanghai Pharmaceutical (Group) Co., Ltd. holds 716,516,039 shares, which is 19.322% of the total[28] - The total share capital of the company at the end of the reporting period was 3,708,361,809 shares, including 2,789,289,105 A shares and 919,072,704 H shares[30] Cash Flow and Investments - Cash flow from operating activities generated a net amount of ¥2.35 billion, down from ¥2.78 billion in the previous year, a decrease of approximately 15.4%[41] - Cash inflow from investment activities significantly increased to ¥52.81 billion, compared to ¥19.35 billion in the same period last year, representing a growth of approximately 173.5%[41] - The company reported an investment income of ¥3.37 billion, a substantial increase from ¥343.49 million in the previous year[38] - The cash flow from operating activities showed a net outflow of CNY -391,042,716.21 in 2025, worsening from CNY -224,559,735.50 in 2024[53] - The cash and cash equivalents at the end of the period were CNY 6,980,854,073.85 in 2025, down from CNY 8,234,133,720.99 in 2024, indicating a decrease of approximately 15.2%[54] Corporate Recognition and ESG - Shanghai Pharmaceuticals has been recognized as one of the top ten enterprises in the "2024 Annual China Pharmaceutical Industry Main Business Revenue Top 100" list[11] - The MSCI ESG rating for the company has been upgraded to AA, reflecting its strong performance in environmental, social, and governance aspects[11]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration for the production of Bromidespasm, a sustained-release tablet used to treat myasthenia gravis, marking a significant milestone in its product development [1] Group 1: Product Approval - The sustained-release tablet of Bromidespasm has been granted a drug registration certificate by the National Medical Products Administration [1] - The drug was originally developed by BAUSCH and was first launched in the United States in 1959 [1] - Shanghai Pharmaceuticals submitted the registration application for this drug in March 2024, which has been accepted by the regulatory authority [1] Group 2: Financial Investment - The company has invested approximately RMB 16.09 million in research and development for this drug as of the date of the announcement [1]

Group 1 - Shanghai Pharmaceuticals has received approval for the production of Bromperidol Sustained-Release Tablets from the National Medical Products Administration [1][2] - The drug is classified as a Class 3 chemical drug with a specification of 0.18g per tablet and has been registered under the approval number H20255730 [2] - The drug is indicated for the treatment of myasthenia gravis and was originally developed by BAUSCH, first launched in the United States in 1959 [3] Group 2 - As of the announcement date, no other companies in China have listed Bromperidol Sustained-Release Tablets [4] - According to IQVIA data, the procurement amount for Bromperidol Tablets in hospitals in mainland China is approximately RMB 60.29 million for 2024 [5] - The company has invested approximately RMB 16.009 million in research and development for this drug [3] Group 3 - The approval of the drug is expected to enhance the market share and competitiveness of Shanghai Pharmaceuticals, benefiting from national policies that support newly registered generic drugs in medical insurance and procurement [6] - The company aims to leverage this experience for future generic drug applications [6]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of bromperidol sustained-release tablets, indicating a significant advancement in its product portfolio [1] Company Summary - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shiyu Chinese and Western Medicine Co., Ltd., has obtained the Drug Registration Certificate for bromperidol sustained-release tablets, with the certificate number 2025S03175 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromidespamine sustained-release tablets, which are indicated for the treatment of myasthenia gravis [1] Group 1 - The product, Bromidespamine sustained-release tablets, was originally developed by BAUSCH and was first launched in the United States in 1959 [1] - The registration certificate number for the approved drug is 2025S03175 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromidespasm, a sustained-release tablet used to treat myasthenia gravis, marking a significant milestone for the company in expanding its product portfolio [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has been granted a Drug Registration Certificate for Bromidespasm, with the certificate number 2025S03175 [1] - The drug was originally developed by BAUSCH and was first launched in the United States in 1959 [1] - The company submitted the registration application for this drug to the National Medical Products Administration in March 2024, which has been accepted [1] - As of the date of the announcement, the company has invested approximately RMB 16.09 million in research and development for this drug [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Bromperidol Sustained-Release Tablets, indicating a significant advancement in its product portfolio [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has been granted a drug registration certificate (Certificate No. 2025S03175) for Bromperidol Sustained-Release Tablets, allowing the company to commence production [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 中國上海，2025 年 10 月 29 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简称：上海医药 编号：临 2025-094 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於溴吡斯的明緩釋片獲得批准生產的公告》、《上海醫 藥集團股份有限公司關 ...

剂型：片剂 规格：0.18g 注册分类：化学药品 3 类 上海医药集团股份有限公司 关于溴吡斯的明缓释片获得批准生产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海上药中西 制药有限公司（以下简称"上药中西"）的溴吡斯的明缓释片（以下简称"该药 品"）收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品注册 证书》（证书编号：2025S03175），该药品获得批准生产。 一、该药品基本情况 药物名称：溴吡斯的明缓释片 证券代码：601607 证券简称：上海医药 编号：临 2025-094 药品批准文号：国药准字 H20255730 1 三、对上市公司影响及风险提示 根据国家相关政策，按新注册分类获批仿制药的品种在医保支付及医疗机构 采购等领域将获得更大的支持力度。因此上药中西的溴吡斯的明缓释片获得批准 生产，有利于扩大该药品的市场份额，提升市场竞争力，同时为公司后续产品开 展仿制药申报积累了宝贵的经验。 因受国家政策、市场环境等不确定因素影响，该药 ...